RBC Capital Downgrades Homology Medicines (FIXX) to Sector Perform
Tweet
Share
E-mailGet Alerts FIXX Hot Sheet
Price: $1.44 -4%
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 24 | New: 19
Rating Summary:
8 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 24 | New: 19
Join SI Premium – FREE
RBC Capital analyst Luca Issi downgraded Homology Medicines (NASDAQ: FIXX) from Outperform to Sector Perform with a price target of $4.00 (from $30.00).
For an analyst ratings summary and ratings history on Homology Medicines click here. For more ratings news on Homology Medicines click here.
Shares of Homology Medicines closed at $3.86 yesterday.
You May Also Be Interested In
- R5 Capital Downgrades Kroger (KR) to Sell, 'particularly vulnerable'
- JPMorgan Downgrades Seven Group Holdings Limited (SVW:AU) (SVNWF) to Neutral
- James Hardie Industries (JHX:AU) (JHX) PT Lowered to AUD40 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
